Claims
- 1. A compound having the structure:
- 2. A compound having the structure:
- 3. A compound having the structure:
- 4. A compound having the structure:
- 5. A compound having the structure:
- 6. A compound having the structure:
- 7. The compound of claims 6, wherein the compound is enantiomerically pure.
- 8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any of claims 1 to 6 and a pharmaceutically acceptable carrier.
- 9. The pharmaceutical composition of claim 8, wherein the amount of the compound is from about 0.01 mg to about 1000 mg.
- 10. The pharmaceutical composition of claim 9, wherein the amount of the compound is from about 0.1 mg to about 500 mg.
- 11. The pharmaceutical composition of claim 10, wherein the amount of the compound is from about 1 mg to about 200 mg.
- 12. The pharmaceutical composition of claim 11, wherein the amount of the compound is from about 10 mg to about 100 mg.
- 13. The pharmaceutical composition of claim 12, wherein the carrier is a liquid and the composition is a solution.
- 14. The pharmaceutical composition of claim 8, wherein the carrier is a solid and the composition is a tablet.
- 15. The pharmaceutical composition of claim 8, wherein the carrier is a gel and the composition is a suppository.
- 16. A process of making a pharmaceutical composition comprising admixing a therapeutically effective amount of the compound of any of claims 1 to 7 and a pharmaceutically acceptable carrier.
- 17. A method of treating a subject suffering from depression, which comprises administering to the subject a dose of the compound of any of claims 1 to 7 effective to treat the subject's depression.
- 18. A method of treating a subject suffering from anxiety, which comprises administering to the subject a dose of the compound of any of claims 1 to 7 effective to treat the subject's anxiety.
- 19. A method of alleviating the symptoms of a disorder in a subject, which comprises administering to the subject a dose of a GalR3 antagonist effective to alleviate the symptoms, wherein the GalR3 antagonist is the compound of any of claims 1 to 7.
- 20. The method of any of claims 17 to 19, wherein the therapeutically effective amount is between about 0.01 and about 1000 mg per day.
- 21. The method of claim 20, wherein the therapeutically effective amount is between about 0.10 and about 500 mg per day.
- 22. The method of claim 21, wherein the therapeutically effective amount is between about 1.0 and about 200 mg per day.
- 23. The method of claim 22, wherein the therapeutically effective amount is between about 10 and about 100 mg per day.
- 24. The method of any of claims 17 to 23, wherein the compound can be administered orally.
- 25. The method of any of claims 17 to 24, wherein the subject is a vertebrate, a mammal, a canine or a human.
- 26. The method of any of claims 17 to 25, wherein the compound is administered in combination with food.
Parent Case Info
[0001] This application claims priority of U.S. Provisional Application No. 60/401,939, filed Aug. 7, 2002, the contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60401939 |
Aug 2002 |
US |